We are live on
!
Find out more
MC
Muhlenkamp & Co Portfolio holdings
AUM
$380M
1-Year Est. Return
43.74%
This Fund
S&P 500
This Quarter
Est. Return
+9.86%
1 Year Est. Return
+43.74%
3 Year Est. Return
+121.38%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$320M
AUM Growth
+$14.8M
(+4.9%)
Cap. Flow
-$7.39M
Cap. Flow
% of AUM
-2.31%
Top 10 Holdings %
Top 10 Hldgs %
59.37%
Holding
27
New
1
Increased
20
Reduced
2
Closed
1
Top Buys
| 1 |
Celanese
CE
|
+$7.54M |
| 2 |
Microchip Technology
MCHP
|
+$4.97M |
| 3 |
BGC Group
BGC
|
+$143K |
| 4 |
Rush Enterprises Class A
RUSHA
|
+$117K |
| 5 |
SLB Ltd
SLB
|
+$116K |
Top Sells
| 1 |
UnitedHealth
UNH
|
+$13.1M |
| 2 |
McKesson
MCK
|
+$8.12M |
| 3 |
SPDR Gold Trust
GLD
|
+$6.66K |
Sector Composition
| 1 | Materials | 20.13% |
| 2 | Financials | 18.09% |
| 3 | Technology | 13.45% |
| 4 | Industrials | 13.4% |
| 5 | Energy | 12.67% |
Similar funds
AC
MW
EAM
RWA
CSWG
BP
NICM
KFS
Muhlenkamp & Co's Q2 2025 Portfolio in Review
As of Q2 2025, Muhlenkamp & Co held 27 positions worth $320M, up 4.9% from $306M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Muhlenkamp & Co's Q2 2025 filing shows 1 new, 20 increased, 2 reduced and 1 closed positions. Its largest new stake was Celanese: 151,208 shares worth $8.37M. The largest sale was UnitedHealth, an estimated $13.1M.
By sector, the portfolio is most concentrated in Materials at 20% of assets, up from 17% a quarter earlier, followed by Financials and Technology.
- Muhlenkamp & Co's largest Q2 2025 buy was Celanese: 151,208 shares worth $8.37M.
- Muhlenkamp & Co added most to Microchip Technology in Q2 2025, an estimated $4.97M increase.
- Muhlenkamp & Co's biggest Q2 2025 reduction was McKesson, cutting an estimated $8.12M.
- Muhlenkamp & Co fully exited UnitedHealth in Q2 2025, selling an estimated $13.1M.
- Muhlenkamp & Co's ten largest holdings make up 59% of its $320M portfolio in Q2 2025.
- Muhlenkamp & Co opened 1 new position and closed 1 in Q2 2025.
- Muhlenkamp & Co's portfolio value rose 4.9% quarter-over-quarter to $320M.
Based on Muhlenkamp & Co's 13F filing for Q2 2025, filed 24 Jul 2025.